242 related articles for article (PubMed ID: 36934274)
41. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
42. A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis.
Yeşilbaş O; Yıldız M; Yozgat CY; Tahaoğlu I; Yazan H; Çakır E; Adrovic A; Şahin S; Barut K; Kasapçopur Ö
Turk J Pediatr; 2021; 63(5):903-908. PubMed ID: 34738372
[TBL] [Abstract][Full Text] [Related]
43. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
44. Serum IgA levels for predicting the development of rapidly progressive interstitial lung disease in dermatomyositis.
Zhang H; Liang R; Yuan X; Zheng Z; Lai W
Respir Med; 2023 Sep; 216():107322. PubMed ID: 37302423
[TBL] [Abstract][Full Text] [Related]
45. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
46. [Dermatomyositis associated with anti-MDA5 autoantibody].
Collado MV; Gargiulo MLÁ; Gómez R; Gómez G; Pérez N; Suarez L; Taratuto AL; Aruj P
Medicina (B Aires); 2018; 78(5):360-363. PubMed ID: 30285929
[TBL] [Abstract][Full Text] [Related]
47. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
48. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
[TBL] [Abstract][Full Text] [Related]
49. Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study.
Yamaguchi K; Nakajima T; Yamaguchi A; Itai M; Onuki Y; Shin Y; Uno S; Muto S; Kouno S; Yatomi M; Aoki-Saito H; Hara K; Endo Y; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Katsumata N; Hirasawa H; Tsushima Y; Maeno T
Clin Rheumatol; 2022 May; 41(5):1473-1481. PubMed ID: 35034225
[TBL] [Abstract][Full Text] [Related]
50. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
51. Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy.
Hama S; Higashida-Konishi M; Akiyama M; Shimada T; Takei H; Izumi K; Oshima H; Okano Y
Intern Med; 2022; 61(7):1085-1091. PubMed ID: 35370250
[TBL] [Abstract][Full Text] [Related]
52. Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease.
Xu L; You H; Wang L; Lv C; Yuan F; Li J; Wu M; Da Z; Wei H; Yan W; Zhou L; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Du Y; Xue J; Zhang M; Tan W
Arthritis Rheumatol; 2023 Apr; 75(4):609-619. PubMed ID: 35849805
[TBL] [Abstract][Full Text] [Related]
53. Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis.
Holzer MT; Nies JF; Oqueka T; Huber TB; Kötter I; Krusche M
Chest; 2023 Jan; 163(1):e1-e5. PubMed ID: 36628678
[TBL] [Abstract][Full Text] [Related]
54. IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies.
Thuner J; Coutant F
Autoimmun Rev; 2023 Oct; 22(10):103420. PubMed ID: 37625674
[TBL] [Abstract][Full Text] [Related]
55. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease.
Nishina N; Sato S; Masui K; Gono T; Kuwana M
RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506053
[TBL] [Abstract][Full Text] [Related]
56. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
57. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
Wakura R; Matsuda S; Kotani T; Shoda T; Takeuchi T
Sci Rep; 2020 Sep; 10(1):15692. PubMed ID: 32973255
[TBL] [Abstract][Full Text] [Related]
58. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
Wang LM; Yang QH; Zhang L; Liu SY; Zhang PP; Zhang X; Liu XJ; Han LS; Li TF
Rheumatology (Oxford); 2022 Aug; 61(9):3704-3710. PubMed ID: 34940809
[TBL] [Abstract][Full Text] [Related]
59. Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine.
Kawamoto S; Abe T; Nagahori K; Yoshino A; Fujii A; Ono Y; Ueda Y; Takeda T
Intern Med; 2022 Jul; 61(13):2007-2012. PubMed ID: 34776485
[TBL] [Abstract][Full Text] [Related]
60. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study.
Wu W; Xu W; Sun W; Zhang D; Zhao J; Luo Q; Wang X; Zhu F; Zheng Y; Xue Y; Wan W; Wu H; Han Q; Ye S
Rheumatology (Oxford); 2021 Dec; 61(1):230-239. PubMed ID: 33764398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
